S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion (2015/1/15)|
|DepoMed to buy U.S. rights to Nucynta from J&J unit (2015/1/15)|
|Depomed Reports Fourth Quarter and Full Year 2014 Financial Results (2015/2/23)|
|Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015 (2015/2/12)|
|Depomed To Present At Healthcare Conferences In February (2015/2/4)|
|New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence (2015/2/9)|
|PDL BioPharma Announces Fourth Quarter and Full Year 2014 Financial Results (2015/2/23)|
|PDL BioPharma Provides Fourth Quarter 2014 Revenue Guidance of $158 Million (2014/12/10)|
|Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution (2015/1/15)|
|Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease (2015/2/4)|
Click above to view more mutual fund data and stats for depo - DepoMed Inc.